Last reviewed · How we verify
Gel-Flow NT
Gel-Flow NT, marketed by Hardeep Singh, holds a position in the pharmaceutical market with its key composition patent set to expire in 2028. The drug's primary strength lies in its current market presence, leveraging its established position to generate consistent revenue. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Gel-Flow NT |
|---|---|
| Sponsor | Hardeep Singh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Depo-Medrol on Psoas After LLIF (PHASE4)
- Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |